NasdaqGS - Nasdaq Real Time Price USD

United Therapeutics Corporation (UTHR)

265.33 +1.06 (+0.40%)
As of 12:24 PM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 5.66M 85.38M 1955
Mr. Michael I. Benkowitz President & COO 3.26M -- 1972
Mr. James C. Edgemond CFO & Treasurer 2.15M -- 1968
Mr. Paul A. Mahon J.D. Executive VP, General Counsel & Corporate Secretary 2.44M 15.71M 1964
Mr. Dewey Steadman C.F.A. Head of Investor Relations -- -- --
Ms. Holly Hobson Associate Vice President of Human Resources -- -- --
Kevin T. Gray Senior Vice President of Strategic Operations & Logistics -- -- --
Mr. Patrick Poisson Executive VP of Technical Operations -- -- 1968
Dr. Leigh Peterson Executive Vice President of Product Development & Xenotransplantation -- -- --
Mr. Gil Golden Senior VP & Chief Medical Officer -- -- --

United Therapeutics Corporation

1000 Spring Street
Silver Spring, MD 20910
United States
301 608 9292 https://www.unither.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,168

Description

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Corporate Governance

United Therapeutics Corporation’s ISS Governance QualityScore as of May 1, 2024 is 3. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 3; Compensation: 4.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

Jul 31, 2024 - Aug 05, 2024
United Therapeutics Corporation Earnings Call

Related Tickers

LQDA Liquidia Corporation
12.26
+1.66%
 
MNKD MannKind Corporation
4.3900
+1.62%
 
ALNY Alnylam Pharmaceuticals, Inc.
150.87
+0.27%
 
HALO Halozyme Therapeutics, Inc.
43.75
+1.39%
 
JAZZ Jazz Pharmaceuticals plc
112.73
+2.82%
 
BMRN BioMarin Pharmaceutical Inc.
80.94
-0.11%
 
INCY Incyte Corporation
57.21
+7.81%
 
ARGX argenx SE
366.88
-2.07%
 
GMAB Genmab A/S
29.37
+1.84%
 
BPMC Blueprint Medicines Corporation
106.55
-0.14%